All In Biotech

Drug Trial Radar · NCT00534677

The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed

Efficacy And Safety Of Terlipressin Vs Octreotide As Adjuvant Therapy In Bleeding Esophageal Varices

Last checked: Nov 20, 2026Latest source record: Dec 5, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 320 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

320

Actual

Start

May 2004

Primary completion

Not stated

Study completion Jul 2005

Sponsor

Lead sponsor
Aga Khan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 26, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Terlipressin and Octreotide are two common agents used as adjuvants in the management of variceal bleeding. Both agents have been claimed equivalent to endoscopic therapy in randomized studies. There are no head to head clinical trials of these two agents available in the literature. We aimed to compare the efficacy and safety of Terlipressin and Octreotide in combination with Endoscopic Variceal band Ligation (EVL)in patients presenting with Esophageal Variceal Bleed (EVB).

Conditions

  • Portal Hypertension
  • Cirrhosis
  • Hematemesis
  • Melena

Interventions

  • TerlipressinDrug

    2 mg stat \& then 1 mg q6h iv and Placebo of Octreotide

  • OctreotideDrug

    Octreotide 50mcg/hr infusion \& a placebo of Terlipressin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety & EfficacyTime frame: 5 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Aga Khan University Hospital

    Karachi, Sindh, Pakistan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.